Skip to main content
Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc — Investor Relations & Filings

Ticker · CNTA ISIN · US1523091007 LEI · 213800GIDAARDSKOI827 US Manufacturing
Open in API
Filings indexed 548 across all filing types
Latest filing 2021-05-12 Regulatory Filings
Country GB United Kingdom
Listing US CNTA

About Centessa Pharmaceuticals plc

https://www.centessa.com/

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that utilizes a Research & Development innovation engine to discover and develop transformational medicines for patients. The company employs a data-driven approach to advance its portfolio of innovative assets. A key program in its pipeline is the development of potential best-in-class, orally administered orexin receptor 2 (OX2R) agonists for the treatment of sleep-wake disorders. Centessa's broader therapeutic focus often includes rare diseases and other areas with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter dated May 12, 2021, addressed to the SEC staff regarding comments on Centessa Pharmaceuticals Ltd's Registration Statement on Form S-1 filed April 21, 2021. The letter responds to SEC comments on the S-1 registration statement, including risk factors, funding requirements, incentivization agreements, and exhibits. It is a correspondence letter responding to regulatory comments on a registration statement, not the registration statement itself or a financial report. The document is a regulatory correspondence related to a filing but does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory communication and response to SEC comments.
2021-05-12 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC for Centessa Pharmaceuticals Limited. It is a registration statement under the Securities Act of 1933, related to an initial public offering (IPO) of American Depositary Shares. The document includes a prospectus with detailed information about the company, its business, management, financials, and offering details. This type of filing is a capital markets registration document used to register securities for public sale and is not an annual report, earnings release, or other financial report. It is a primary registration statement for a securities offering, which falls under Capital/Financing Update filings. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a certification, but a full registration statement amendment.
2021-05-12 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed letter from Centessa Pharmaceuticals Limited to the SEC regarding a confidential treatment request related to their Registration Statement on Form S-1. It discusses the company's valuation methods for its ordinary shares in preparation for an IPO, including third-party valuations, fair value determinations, and share capital reorganization. The document references the Registration Statement on Form S-1, which is a filing related to securities registration for an initial public offering. The content is focused on regulatory correspondence and confidential treatment requests rather than financial results, management changes, or other report types. It is not a full financial report, earnings release, or management discussion but a regulatory filing responding to SEC comments and requesting confidential treatment of sensitive information. Therefore, the document fits best under Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or certification but a substantive regulatory communication.
2021-05-11 English
Regulatory Filings 2021
Regulatory Filings
2021-04-21 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Centessa Pharmaceuticals Ltd to the SEC staff regarding comments on their Draft Registration Statement on Form S-1. It discusses amendments to the registration statement, clarifications on business model, pipeline, financial data, risk factors, and other disclosures typically required in an S-1 filing. The document is not a financial report like an Annual Report or Interim Report, nor is it an earnings release or a call transcript. It is a regulatory filing responding to SEC comments on a registration statement, which is a typical regulatory compliance document. The length and content indicate it is not a brief announcement or a proxy statement. Therefore, the best classification is Regulatory Filings (RNS), as it is a regulatory correspondence and amendment submission to the SEC that does not fit other specific categories.
2021-04-21 English
S-1 Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) to register securities for sale to the public. It includes detailed information such as the prospectus, risk factors, use of proceeds, capitalization, management discussion and analysis, business description, management, executive compensation, principal shareholders, and financial statements. This type of filing is not an annual report, earnings release, or any other report type listed but is specifically related to capital raising and securities registration. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice, confirming it is a primary filing of this type.
2021-04-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.